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Abstract
Background: This article summarizes the European Renal Association – European Dialysis and Transplant Association
Registry’s 2014 annual report. It describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease
(ESRD) in 2014 within 35 countries.
Methods: In 2016, the ERA-EDTA Registry received data on patients who in 2014 where undergoing RRT for ESRD, from 51
national or regional renal registries. Thirty-two registries provided individual patient level data and 19 provided aggregated
patient level data. The incidence, prevalence and survival probabilities of these patients were determined.
Results: In 2014, 70 953 individuals commenced RRT for ESRD, equating to an overall unadjusted incidence rate of 133 per
million population (pmp). The incidence ranged by 10-fold; from 23 pmp in the Ukraine to 237 pmp in Portugal. Of the pa-
tients commencing RRT, almost two-thirds were men, over half were aged65 years and a quarter had diabetes mellitus as
their primary renal diagnosis. By day 91 of commencing RRT, 81% of patients were receiving haemodialysis. On 31
December 2014, 490 743 individuals were receiving RRT for ESRD, equating to an unadjusted prevalence of 924 pmp.
This ranged throughout Europe by more than 10-fold, from 157 pmp in the Ukraine to 1794 pmp in Portugal. In 2014, 19 406
kidney transplantations were performed, equating to an overall unadjusted transplant rate of 36 pmp. Again this varied
considerably throughout Europe. For patients commencing RRT during 2005–09, the 5-year-adjusted patient survival proba-
bilities on all RRT modalities was 63.3% (95% confidence interval 63.0–63.6). The expected remaining lifetime of a 20- to 24-
year-old patient with ESRD receiving dialysis or living with a kidney transplant was 21.9 and 44.0 years, respectively. This
was substantially lower than the 61.8 years of expected remaining lifetime of a 20-year-old patient without ESRD.
Key words: dialysis, epidemiology, ESRD, kidney transplantation, survival analysis
Introduction
The European Renal Association – European Dialysis and Transplant
Association (ERA-EDTA) Registry’s annual report describes the epi-
demiology of renal replacement therapy (RRT) for end-stage renal
disease (ESRD) within Europe and adjacent countries based on data
collected via the national and regional renal registries [1]. On an an-
nual basis, we publish a summary of the ERA-EDTA Registry’s an-
nual report that is intended to provide the reader with an overview
of the current status of RRT for ESRD in Europe [2–4]. In 2016, we
received the 2014 data from 51 national or regional renal registries in
35 countries covering a general population of 531.7 million people.
This represented 65.4% of the 2014 European general population.
Thirty-two national or regional renal registries from 17 countries pro-
vided individual patient data, whereas 19 countries or regions pro-
vided aggregated data (see Appendix 1). The proportion of the
European population covered by the ERA-EDTA Registry in 2014 was
lower than that of 2013 (73.6%) due to the absence of Russia and
Slovenia from this year’s annual report.
This summary presents the 2014 incidence and prevalence
of patients receiving RRT, kidney transplantation activity and
the patient and graft survival in these 35 countries. The meth-
ods used to derive the results presented in this overview, along
with the full results, can be found in the ERA-EDTA Registry
2014 Annual Report [1].
Incidence of RRT
In 2014, 70 953 individuals commenced RRT for ESRD, which
equated to an overall unadjusted incidence rate of 133 per
million population (pmp, Table 1). The unadjusted incidence
rate was highest in Portugal (237 pmp), Greece (218 pmp) and
Cyprus (204 pmp), whereas it was lowest in the Ukraine (23
pmp) and Iceland (58 pmp, Table 1 and Figures 1 and 2). Of the
patients commencing RRT, the majority were men (63%), over
half were aged65 years (55%) and a quarter had diabetes melli-
tus (26%) as their primary renal diagnosis (Figure 3). The mean
age of the patients commencing RRT in all countries and re-
gions combined was 64.6 years (Table 1). However, this ranged
from a mean age of 55.1 years in Albania to 70.1 years in Dutch-
speaking Belgium. Of the incident patients alive and receiving
RRT at day 91 after the start of treatment, the majority were
receiving haemodialysis (81%), 13% were receiving peritoneal
dialysis and 6% were living with a kidney transplant (Figure 4).
However, the modality of RRT at day 91 after the start of treat-
ment varied considerably between age groups; as the age of the
patient increased the proportion of patients receiving either
peritoneal dialysis or living with a kidney transplant decreased.
Furthermore, patients with a primary renal diagnosis of dia-
betes mellitus were half as likely to have a kidney transplant by
day 91 compared with the non-diabetic group (3% versus 7%).
Prevalence of RRT
On 31 December 2014, 490 743 individuals were receiving RRT
for ESRD (Table 2). This equated to an unadjusted prevalence of
924 pmp. Again there was considerable variation between coun-
tries, with the highest unadjusted prevalence rates seen in
Portugal (1794 pmp), the Spanish regions of Catalonia (1312
pmp), Valencia (1298 pmp), Galicia (1265 pmp) and Murcia (1258
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Table 1. Incidence of RRT in 2014 at day 1, for all primary renal diseases combined and diabetes mellitus types 1 and 2, by count (N) and un-
adjusted rate per million population, and for all primary renal diseases combined, the mean age at the start of RRT, presented by country/
region
General population covered
by the registry in thousands
Incidence in 2014 at day 1
Total N Total pmp Mean age DM N DM pmp
Albania 2863 252 88 55.1 30 11
Austria 8508 1036 122 64.2 259 30
Belgium, Dutch-speakinga 6444 1145 178 70.1 207 32
Belgium, French-speakinga 4788 828 173 67.5 188 39
Bosnia and Herzegovina 3508 421 120 60.7 125 36
Bulgariab 7217 1197 166 281 39
Croatia 4070 640 157 63.7 186 46
Cyprus 847 173 204 64.6 58 69
Czech Republicb 10 222 2017 197
Denmark 5700 748 131 64.2 184 32
Estonia 1315 115 88 61.1 20 15
Finland 5462 461 84 59.3 165 30
France 66 262 10 791 163 67.6 2379 36
Georgia 4491 743 166 58.4 159 35
Greece 10 892 2372 218 69.7 575 53
Iceland 327 19 58 62.0 1 3
Israel 8216 1668 203 64.6 807 98
Italy (6 of 20 regions) 21 274 3243 152 68.6 558 26
Latvia 1590 152 96 63.3 23 15
Lithuania 2943 306 104 57.8 48 16
Macedonia 2022 268 133 63.2 62 31
Montenegroa 622 58 93 56.2 20 32
Norway 5137 523 102 62.4 90 18
Poland 36 338 4341 120
Portugal 10 427 2473 237 790 76
Romania 19 710 2997 152 61.1 442 22
Serbia 7131 985 138 61.2 250 35
Slovakia 5421 831 153 63.8 316 58
Spain 46 771 6229 133 63.0 1520 33
Spain, Andalusia 8394 1046 125 62.6 270 32
Spain, Aragon 1329 163 123 64.1 40 30
Spain, Asturias 1059 147 139 64.5 33 31
Spain, Basque country 2166 241 111 65.5 39 18
Spain, Cantabriaa 587 61 104 61.4 12 21
Spain, Castile and Leona 2487 299 120 67.6 79 32
Spain, Castile-La Manchaa 2069 252 122 63.7 62 30
Spain, Catalonia 7519 1178 157 66.0 259 34
Spain, Extremadura 1100 124 113 66.0 28 26
Spain, Galicia 2741 398 145 65.0 114 42
Spain, Community of Madrid 6454 828 128 64.3 201 31
Spain, Region of Murcia 1467 194 132 62.9 46 31
Spain, Navarrea 636 83 130 65.0 14 22
Spain, Valencian region 5005 704 141 65.9 156 31
Sweden 9696 1168 121 62.5 273 28
Switzerlandc 8230 800 97 64.5 157 19
The Netherlands 16 865 1941 115 63.6 358 21
Tunisia, Sfax region 1186 165 139 60.1 59 50
Turkeyd 77 696 11 447 147 1042 13
Ukraine 42 903 998 23 196 5
UK, Englanda 54 317 6311 116 62.3 1441 27
UK, Northern Irelanda 1840 170 92 64.6 39 21
UK, Scotland 5348 557 104 58.8 164 31
UK, Walesa 3092 364 118 65.5 94 30
All countries 531 690 70 953 133 64.6 13 566 32
When cells are left empty, the data are unavailable and, therefore, could not be used for the calculation of the summary data.
DM, diabetes mellitus as cause of renal failure.
aPatients younger than 20 years of age are not reported. The true incidence counts are, therefore, slightly higher than the counts reported here.
bData on incidence include dialysis patients only.
cData on incidence of cause of renal failure (DM) include dialysis patients only.
dData on incidence of cause of renal failure (DM) are based on 2836 of 11 447 patients (24.8%).
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pmp), and French- and Dutch-speaking Belgium (1250 pmp and
1238 pmp, respectively, Table 2 and Figures 5 and 6). The un-
adjusted prevalence of RRT was considerably lower in the
Ukraine (157 pmp) and Albania (374 pmp). Of the prevalent pa-
tients, the majority were men (60%); however, now just under
half were aged65 years (44%) and a fifth had diabetes mellitus
(19%) as their primary renal diagnosis (Figure 7). The mean age
of the prevalent patients receiving RRT in all countries and re-
gions combined was 60.9 years (Table 2). This ranged from a
mean age of 51.4 years in Albania to 66.4 years in Portugal. The
majority of prevalent patients were receiving haemodialysis
(57%), just over a third of patients were living with a kidney
transplant (37%) and only 5% were receiving peritoneal dialysis
(Figure 8). Once again the modality of RRT varied considerably
between age groups; as the age of the prevalent patients
increased the proportion living with a kidney transplant
decreased. For those aged 20–44 years, 65% were living with a
kidney transplant, whereas this was only 40% of patients aged
65–74 years. Again prevalent patients with a primary renal diag-
nosis of diabetes mellitus were much less likely to be living
with a kidney transplant compared with the non-diabetic group
(28% versus 49%).
Kidney transplantation
In 2014, 19 406 kidney transplantations were performed that
equated to an overall unadjusted transplant rate of 36 pmp
(Figure 9). Again this figure varied considerably between
Fig. 1. Unadjusted incident rates per million population by country/region at day 1 in 2014. The incident rates for Bulgaria and the Czech Republic only include patients
receiving dialysis.
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countries with the highest unadjusted transplant rates seen in
the Netherlands (59 pmp), Spain (57 pmp) and Norway (53 pmp),
with some Spanish regions reaching even higher rates.
Conversely, the lowest unadjusted transplant rates were re-
ported in the Ukraine (2 pmp), Georgia (6 pmp) and Bulgaria (7
pmp). Overall the unadjusted deceased donor transplant rate
was more than double that of the unadjusted living donor
transplant rate (27 pmp versus 12 pmp, Figure 10; 68% versus
31%, Figure 11). The highest unadjusted rates of deceased donor
transplants were seen in Spain (48 pmp), Croatia (46 pmp) and
the Czech Republic (43 pmp, Figure 10), whereas the highest un-
adjusted rate of living donor transplants were seen in the
Netherlands (31 pmp), Turkey (30 pmp) and Northern Ireland
(28 pmp, Figure 10).
Survival of patients receiving RRT
For patients commencing RRT in the period 2005–09, the 1-, 2-
and 5-year-adjusted patient survival probabilities on all RRT
modalities were 90.0% [95% confidence interval (CI) 89.9–90.2],
Fig. 2. Unadjusted (left panel) and adjusted (right panel) incident rates per million population by country/region at day 1 in 2014. Registries providing individual patient
data are shown as dark bars and registries providing aggregated data as light bars. The incident rate for Bulgaria and the Czech Republic only includes patients receiv-
ing dialysis.
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82.8% (95% CI 82.6–83.0) and 63.3% (95% CI 63.0–63.6), respect-
ively (see Appendix 2 and Table 3 for a description of the adjust-
ments made and the countries/regions included in this
analysis). For the same cohort of patients commencing dialysis
between 2005 and 2009, the 1-, 2- and 5-year-adjusted patient
survival probabilities (with kidney transplantation considered
as a censored event) were 88.1% (95% CI 87.9–88.2), 79.5% (95%
CI 79.2–79.7) and 55.7% (95% CI 55.3–56.1), respectively. Patient
survival after a first kidney transplant performed during 2005
and 2009 was much better than for those patients receiving dia-
lysis (Figure 12). For those with a transplant, 5-year-adjusted pa-
tient and graft survival remain higher with a living donor
transplant compared with a deceased donor transplant [95.7%
(95% CI 95.2–96.2) versus 92.3% (95% CI 91.9–92.7) for patient sur-
vival and 87.0% (95% CI 86.3–87.8) versus 81.6% (95% CI 81.1–
82.2) for graft survival. See Appendix 2 and Table 3 for a descrip-
tion of the adjustments made and the countries/regions
included in this analysis.].
Expected remaining lifetime
There remains a substantial difference in the expected re-
maining lifetime between the general population and those
receiving dialysis (Figure 13). Patients aged 20–45 years old
Fig. 3. Unadjusted incident percentages by (A) gender, (B) age and (C) primary
renal diagnosis at day 1 in 2014. See Appendix 1 for a list of countries and re-
gions supplying individual patient level or aggregated level data.
Fig. 4. Unadjusted incident percentages of (A) established therapy overall, and
established therapy by (B) gender, (C) age and (D) primary renal diagnosis at day
91 in 2014. (B)–(D) are only based on data from registries providing individual pa-
tient data. See Appendix 1 for a list of countries and regions supplying individ-
ual patient level or aggregated level data. HD, haemodialysis; PD, peritoneal
dialysis; Tx, transplant; DM, diabetes mellitus.
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Table 2. Prevalence of RRT on 31 December 2014, for all primary renal diseases combined and diabetes mellitus types 1 and 2, by count (N) and
unadjusted rate per million population, and for all primary renal diseases combined, the mean age of prevalent patients, presented by coun-
try/region
General population covered
by the registry in thousands
Prevalent patients on RRT in 2014
Total N Total pmp Mean age DM N DM pmp
Albania 2863 1072 374 51.4 120 42
Austria 8508 9038 1062 60.8 1791 211
Belgium, Dutch-speakinga 6444 7980 1238 65.5 1379 214
Belgium, French-speakinga 4788 5983 1250 64.6 1035 216
Bosnia and Herzegovina 3508 2662 759 59.4 501 143
Bulgaria 7217 4168 578
Croatia 4070 4295 1055 64.6 1246 306
Cyprus 847
Czech Republic 10 222 10 931 1069
Denmark 5700 5164 906 58.4 869 153
Estonia 1315 834 634 57.8 155 118
Finland 5462 4571 837 58.8 1167 214
France 66 262 80 144 1210 62.2 12 604 190
Georgia 4491 2096 467 56.1 435 97
Greece 10 892 13 101 1203 63.8 2399 220
Iceland 327 221 675 56.0 24 73
Israelb 8216 6286 765 60.9 2909 354
Italy (6 of 20 regions) 21 274 24 721 1162 61.8 2941 138
Latvia 1590 996 627 55.7 97 61
Lithuania 2943 2146 729
Macedonia 2022 1543 763 56.9 225 111
Montenegroa 622 296 476 52.4 47 76
Norway 5137 4716 918 59.1 628 122
Poland 36 338 31 106 856
Portugalc 10 427 18 703 1794 66.4 3332 320
Romaniad 19 710 17 620 894 59.9 1897 96
Serbia 7131 5860 822 58.3 936 131
Slovakiab 5421 3273 604 62.7 1067 197
Spain 46 771 55 062 1177 59.5 7630 163
Spain, Andalusia 8394 9537 1136 60.0 1427 170
Spain, Aragon 1329 1524 1147 62.5 268 202
Spain, Asturias 1059 1228 1160 62.4 201 190
Spain, Basque country 2166 2571 1187 61.5 264 122
Spain, Cantabriaa 587 601 1025 61.0 85 145
Spain, Castile and Leona 2487 2696 1084 63.8 467 188
Spain, Castile-La Manchaa 2069 2180 1054 61.6 335 162
Spain, Catalonia 7519 9863 1312 62.3 1410 188
Spain, Extremadura 1100 1221 1110 61.4 191 174
Spain, Galicia 2741 3468 1265 61.9 600 219
Spain, Community of Madrid 6454 6739 1044 61.4 1183 183
Spain, Region of Murcia 1467 1845 1258 61.7 251 171
Spain, Navarrea 636 714 1122 61.9 79 124
Spain, Valencian region 5005 6495 1298 62.7 853 170
Sweden 9696 9263 955 59.5 1641 169
Switzerlandb 8230 2834 344 68.1 540 66
The Netherlands 16 865 16 311 967 59.9 1991 118
Tunisia, Sfax regionb 1186 806 678 58.2 140 118
Turkeye 77 696 71 318 918 2821 36
Ukraine 42 903 6742 157 902 21
UK, Englanda 54 317 49 698 915 58.4 8043 148
UK, Northern Irelanda 1840 1598 868 58.2 243 132
UK, Scotland 5348 4757 890 56.5 724 135
UK, Walesa 3092 2828 915 59.5 483 156
All countries 531 690 490 743 924 60.9 62 962 155
When cells are left empty, the data are unavailable and, therefore, could not be used for the calculation of the summary data.
DM, diabetes mellitus as cause of renal failure.
aPatients younger than 20 years of age are not reported. The true prevalent counts are, therefore, slightly higher than the counts reported here.
bData on prevalence include dialysis patients only.
cData on prevalence of cause of renal failure (DM) include dialysis patients only.
dThe overall prevalence of RRT is underestimated by approximately 3% due to an estimated 30% underreporting of patients living on a functioning graft.
eData on the prevalence of cause of renal failure (DM) are based on 8897 of 71 318 patients (12.5%).
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receiving dialysis are expected to live only one-third as long
as the age-matched general population. The prospect is even
worse for patients aged 55–64 years, as they are expected to
live only a quarter as long as their age-matched counterparts
in the general population. Patients living with a kidney
transplant fare better than their counterparts receiving
dialysis. However, for the transplant recipients aged 20–49
years their life expectancy is still approximately one-third
less than that of the age-matched general population. As the
age of the transplant recipient increases, the disparity in life
Fig. 5. Unadjusted prevalence per million population by country/region on 31 December 2014. The prevalence rates for Israel, Slovakia, Switzerland and Tunisia (Sfax
region) only include patients receiving dialysis. For Romania, the overall prevalence of RRT is underestimated by 3% due to an estimated 30% underreporting of pa-
tients living on a functioning graft.
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expectancy with the age-matched general population also
increases.
Affiliated registries
Albanian Renal Registry (M. Barbullushi, A. Koroshi and all team
of Nephrology); Austrian Dialysis and Transplant Registry
(OEDTR) (R.K.); Dutch-speaking Belgian Society of Nephrology
(NBVN) (B. De Moor, F. Schroven and J. De Meester); French-
speaking Belgian Society of Nephrology (GNFB) (J.M.d.G. and F.
Collart); Renal Registry Bosnia and Herzegovina (H.R., L. Lukic
and S. Coric); Bulgaria (E.S.V., I. Velinova and M. Gitcheva);
Croatian Registry of Renal Replacement Therapy (CRRRT) (I.B., S.
Racki and N. Jankovic); Cyprus Renal Registry (K.I. and all of the
renal units providing data); Czech Republic: Registry of Dialysis
Patients (RDP) (I. Rychlık, J. Potucek and F.L.); Danish
Nephrology Registry (DNS) (J.G.H.); Estonian Society of
Nephrology (€U. Pechter, M.R. and K. Lilienthal); Finnish Registry
for Kidney Diseases (P.F. and C. Gro¨nhagen-Riska); France: The
Epidemiology and Information Network in Nephrology (REIN)
(M.L. and C. Couchoud); Georgian Renal Registry (N.K. and
Dialysis Nephrology and Transplantation Union of Georgia);
Hellenic Renal Registry (N.A.); Icelandic End-Stage Renal
Disease Registry (R.P.); Israel National Registry of Renal
Replacement Therapy (R. Dichtiar, T. Shohat and E.G.); Italian
Registry of Dialysis and Transplantation (RIDT) (M.N., M.
Fig. 6. Unadjusted (left panel) and adjusted (right panel) prevalence per million population by country/region on 31 December 2014. Registries providing individual pa-
tient data are shown as dark bars and registries providing aggregated data as light bars. The prevalence rates for Israel, Slovakia, Switzerland and Tunisia (Sfax region)
only include patients receiving dialysis. For Romania, the overall prevalence of RRT is underestimated by 3% due to an estimated 30% underreporting of patients living
on a functioning graft.
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Postorino and A. Limido); Latvian Renal Registry (H.C. and V.
Kuzema); Lithuanian Renal Registry (V. Kuzminskis, I.A.
Bumblyt _e and E.Z.); Macedonian Renal Registry (L. Trpenovski,
Z. Seljami and O.S.-T.); Montenegrin Renal Registry (M.R., D.
Radunovic and V. Prelevic); Norwegian Renal Registry (T.
Leivestad, A.V. Reisæter and A.A˚.); Polish Renal Registry (B.R., M.
Klinger and G. Korejwo); Portuguese Renal Registry (F.M., F.
Nolasco and R. Filipe); Romanian Renal Registry (RRR) (G.
Mircescu, L.G. and E. Podgoreanu); Renal Registry in Serbia
(Working Group of Serbian RRT Registry and all of the Serbian
renal units); Slovakian Renal Registry (V.S., I. Lajdova and M.
Karolyova); Spanish RRT National Registry at ONT, Spanish
Regional Registries and Spanish Society of Nephrology (SEN)
and the regional registries of Andalusia (SICATA) (P.C.d.l.N.),
Aragon (J.I. Sanchez Miret and J.M. Abad Diez), Asturias (R.
A.d.l.T., J.R. Quiros and RERCA Working Group), Basque country
Fig. 8. Unadjusted prevalent percentages of (A) established therapy overall, and
established therapy by (B) gender, (C) age and (D) primary renal diagnosis on 31
December 2014. (B)–(D) are only based on data from registries providing individ-
ual patient data. See Appendix 1 for a list of countries and regions supplying in-
dividual patient level or aggregated level data. HD, haemodialysis; PD,
peritoneal dialysis; Tx, transplant; DM, diabetes mellitus.
Fig. 7. Unadjusted prevalent percentages by (A) gender, (B) age and (C) primary
renal diagnosis on 31 December 2014. See Appendix 1 for a list of countries and
regions supplying individual patient level or aggregated level data.
164 | M. Pippias et al.
Fig. 9. Kidney transplants performed in 2014, as counts and per million population (unadjusted) by country/region. Registries providing individual patient data are
shown as dark bars and registries providing aggregated data as light bars. Data based on patients aged 20 years in Dutch-speaking Belgium, French-speaking
Belgium, Montenegro, the Spanish regions of Cantabria, Castile and Leon, Castile-La Mancha and Navarre, and the UK: England, Northern Ireland and Wales. The total
count for Austria is based on residents and non-residents. For Romania the transplantation activity reflects 70% of the total transplantation activity in the country due
to an underreporting of pre-emptive transplantation.
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(UNIPAR) (A.M., J. Aranzabal, M. Rodrigo and I. Moina), Cantabria
(M. Arias Rodrıguez and O. Garcıa Ruiz), Castile and Leon (R.G.
and C. Fernandez-Renedo), Castile-La Mancha (G. Gutie´rrez
Avila and I.M.A.), Catalonia (RMRC) (E. Arcos, J. Comas and J.
Tort), Extremadura (J.M. Ramos Aceitero and M.A.G.B.), Galicia
(E.B.C. and J. Sanchez-Iba~nez), Community of Madrid (M.I.A.M.),
Renal Registry of the Region of Murcia (C.S.d.P. and I. Marın
Sanchez), Navarre (M.F.S.R., J. Manrique Escola and J. Arteaga
Coloma) and the Valencian region (REMRENAL) (C. Alberich
Martı and M.F.A.); Swedish Renal Registry (SNR) (K.G. Pru¨tz,
M.E.S., M. Evans, S. Scho¨n, L. B€ackman and M. Segelmark); Swiss
Dialysis Registry (P. Ambu¨hl and R. Winzeler); Dutch Renal
Registry (RENINE) (M.H.H. and A. Hemke); Tunisia, Sfax region
(D. Zalila, S. Toumi and F.J.); Registry of the Nephrology, Dialysis
and Transplantation in Turkey (TSNNR) (G. Su¨leymanlar, N.S.
and K. Ates¸); Ukrainian Renal Data System (URDS) (M.K., S.
Fig. 10. Unadjusted deceased donor (left panel) and living donor (right panel) kidney transplants per million population performed in 2014 by country/region. Registries
providing individual patient data are shown as dark bars and registries providing aggregated data as light bars. Data based on patients aged 20 years in Dutch-speak-
ing Belgium, French-speaking Belgium, Montenegro, the Spanish regions of Cantabria, Castile and Leon, Castile-La Mancha and Navarre, and the UK: England,
Northern Ireland and Wales. The total count for Austria is based on residents and non-residents. For Romania, the transplantation activity reflects 70% of the total
transplantation activity in the country due to an underreporting of pre-emptive transplantation.
Fig. 11. Percentage of kidney transplants performed in 2014 by kidney donor
type. See Appendix 1 for a list of countries and regions supplying individual pa-
tient level or aggregated level data.
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Appendix 1
Countries or regions providing individual patient level data. Austria,
Dutch-speaking Belgium, French-speaking Belgium, Bosnia and
Herzegovina, Denmark, Estonia, Finland, France, Greece, Iceland,
Montenegro, Norway, Romania, Serbia, the Spanish regions of
Andalusia, Aragon, Asturias, Basque country, Cantabria, Castile
and Leon, Castile-La Mancha, Catalonia, Extremadura, Galicia,
Community of Madrid, Murcia, Navarre and Valencian region,
Sweden, the Netherlands, UK (England/Northern Ireland/Wales)
and UK (Scotland).
Countries or regions providing aggregated patient level data.
Albania, Bulgaria, Croatia, Cyprus, Czech Republic, Georgia,
Israel, Italy, Latvia, Lithuania, Macedonia, Poland, Portugal,
Slovakia, Spain, Switzerland, Tunisia (Sfax region), Turkey and
Ukraine.
Appendix 2
Analyses for patient survival on RRT and dialysis were adjusted
using the following fixed values: age (60 years), gender (60% men)
and primary renal diagnosis (20% diabetes mellitus, 17% hyper-
tension/renal vascular disease, 15% glomerulonephritis and 48%
other causes).
Analyses for patient and graft survival after a first kidney
transplant were adjusted using the following fixed values: age
(45 years), gender (60% men) and primary renal diagnosis (10%
diabetes mellitus, 8% hypertension/renal vascular disease, 28%
glomerulonephritis and 54% other causes).
The survival analyses presented here were based on data
from Austria, Dutch- and French-speaking Belgium,
Denmark, Finland, France, Greece, Iceland, Norway, the
Spanish regions of Andalusia, Aragon, Asturias, Basque coun-
try, Cantabria, Castile and Leon, Castile-La Mancha,
Catalonia, Extremadura, Galicia and Valencian region,
Sweden, the Netherlands and the UK.
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